FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.

Pacini, P; Rinaldini, M; Algeri, R; Guarneri, A; Tucci, E; Barsanti, G; Neri, B; Bastiani, P; Marzano, S; Fallai, C

Pacini, P; Rinaldini, M; Algeri, R; Guarneri, A; Tucci, E; Barsanti, G; Neri, B; Bastiani, P; Marzano, S; Fallai, C.

Affiliation

Pacini P; U.O. Radioterapia Oncologica, Day Hospital Oncologico, Azienda Ospedaliera Careggi, Firenze, Italy.

Eur J Cancer ; 36(8): 966-75, 2000 May.

Article in En | MEDLINE | ID: mdl-10885599

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Adult; Aged; Algorithms; Cyclophosphamide/administration & dosage; Epirubicin/administration & dosage; Female; Fluorouracil/administration & dosage; Humans; Middle Aged; Mitomycin/administration & dosage; Neoplasm Metastasis; Survival Analysis; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Eur J Cancer Year: 2000 Type: Article Affiliation country: Italy

Search on Google

XML

PubMed Links